BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

...treat solid tumors.FogPharma is also developing a YAP/TAZ-blocker...
...inhibitors CBLB, which regulates T cell proliferation. The YAP/TAZ-TEAD...
...β-cateninTCF (HNF4A) – Hepatocyte nuclear factor 4 αTAZ (WWTR1) –...
BioCentury | May 28, 2020
Distillery Therapeutics

Increasing WWTR1 degradation for NASH

...DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Promoting proteasomal degradation of the transcription factor WWTR1 by...
...proteins GRAMD1B and GRAMD1C activate SAC, which in turn triggers a RHOA-mediated pathway that suppresses WWTR1...
...WWTR1 affects the efficacy of undisclosed drugs in clinical trials for NASH. TARGET/MARKER/PATHWAY: WW domain containing transcription regulator 1 (WWTR1; TAZ...
BioCentury | Jan 29, 2020
Distillery Therapeutics

WWTR1-AXL-ABL2 axis inhibition for brain metastases in lung cancer

...DISEASE CATEGORY: Cancer INDICATION: Lung cancer Blocking a signaling loop comprised of the transcription factor WWTR1...
...and ABL2 signal between each other, and ABL2 activates WWTR1. In patients, high levels of WWTR1...
...tyrosine kinase (ABL2); AXL receptor tyrosine kinase (AXL; UFO); BCR-ABL tyrosine kinase (BCR-ABL); WW domain containing transcription regulator 1 (WWTR1; TAZ...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

...TET2 - Tet methylcytosine dioxygenase 2; WDR5 - WD repeat domain 5; WWTR1 (TAZ) - WW domain containing transcription regulator 1...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

...DLC1 and phosphorylation of AMOTL2 promote invasiveness by activating Yes-associated protein 1 (YAP1; YAP)-WW domain containing transcription regulator 1 (WWTR1; TAZ...
BioCentury | Jan 3, 2017
Distillery Therapeutics

Cardiovascular

...suggest inhibiting YAP1 or its paralog WWTR1 could help treat atherosclerosis. Levels of YAP1 and WWTR1...
...mice. In a mouse model of atherosclerosis, endothelial cell-specific knockdown of YAP1, systemic knockdown of WWTR1...
...WWTR1 inhibitors in animal models of atherosclerosis. TARGET/MARKER/PATHWAY: Yes-associated protein 1 (YAP1; YAP); WW domain containing transcription regulator 1 (WWTR1; TAZ...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Hepatic

...Patient sample and mouse studies suggest inhibiting WWTR1 could help treat NASH. In obese patients, WWTR1...
...fibrosis in the liver compared with normal WWTR1 expression. Next steps include identifying and testing WWTR1...
...steps include identifying and testing WWTR1 inhibitors in mouse models of NASH. TARGET/MARKER/PATHWAY: WW domain containing transcription regulator 1 (WWTR1; TAZ...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); WW domain containing transcription regulator 1 (WWTR1; TAZ)

...Neurology INDICATION: Pain Rat studies suggest inhibiting YAP1 or its paralog WWTR1 could help treat neuropathic...
...pain, siRNA targeting YAP1 delayed the onset of mechanical allodynia and siRNA targeting YAP1 or WWTR1...
...market Visudyne to treat choroidal neovascularization (CNV) TARGET/MARKER/PATHWAY: Yes-associated protein 1 (YAP1; YAP); WW domain containing transcription regulator 1 (WWTR1; TAZ...
Items per page:
1 - 8 of 8